VisiQuate Announces Deployment of AI-Based Analytics for Fresenius Medical Care
Company Integrates Best-In-Industry Intelligent Automation and Analytics to Deliver Predictive Prioritization on Claims
VisiQuate Inc. is pleased to announce that Fresenius Medical Care North America (FMCNA) has expanded a pilot program into a system-wide deployment of two of VisiQuate’s leading analytics solutions: Denials Management Analytics and Denial Flo. FMCNA is the leading provider of kidney care products and services including life-sustaining dialysis treatment for patients with kidney failure.
“When we first talked to the revenue cycle team at Fresenius Medical Care, it was clear they were ready to move to the next level,” VisiQuate’s co-Founder and Chief Experience Officer Rich Waller said. “They did some research, and quickly realized our Denial Flo solution could be ideal for them, because of the way it intelligently segments denials into prioritized worklists and assigns each account to the employee who could most effectively convert it into a paid claim.”
Recommended AI News: Moody’s Analytics Wins an Artificial Intelligence Award
As an evidence-based organization, FMCNA decided to begin with a 90-day pilot of VisiQuate’s Denial Flo solution. They began to see measurable results in a very short time, including enthusiastic adoption by their users, who were impressed by the ways it made them more productive. As a result, FMCNA decided to move ahead with the full deployment of Denial Flo, and added VisiQuate Denials Management Analytics, as well.
“One of our strongest advantages is speed to value,” Brian Robertson, VisiQuate’s Founder and CEO, said. “The time, collaboration, and enthusiasm that Fresenius Medical Care put into this collaboration is a key reason why our pilot went so well.”